Mark Reid

470 total citations
13 papers, 352 citations indexed

About

Mark Reid is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Pharmacology. According to data from OpenAlex, Mark Reid has authored 13 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Public Health, Environmental and Occupational Health, 6 papers in Infectious Diseases and 3 papers in Pharmacology. Recurrent topics in Mark Reid's work include Mosquito-borne diseases and control (7 papers), Malaria Research and Control (6 papers) and Viral Infections and Vectors (5 papers). Mark Reid is often cited by papers focused on Mosquito-borne diseases and control (7 papers), Malaria Research and Control (6 papers) and Viral Infections and Vectors (5 papers). Mark Reid collaborates with scholars based in United States, Australia and France. Mark Reid's co-authors include Peter Nasveld, John Aaskov, Ivor Harris, Michael D. Edstein, Colin Ohrt, Leonard A. Brennan, Karen McCarthy, Bryan Smith, Niranjan Kanesa-thasan and Peter A. Leggat and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Virology.

In The Last Decade

Mark Reid

13 papers receiving 320 citations

Peers

Countries citing papers authored by Mark Reid

Since Specialization

Citations

This map shows the geographic impact of Mark Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Reid more than expected).

Fields of papers citing papers by Mark Reid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Reid. The network helps show where Mark Reid may publish in the future.

Co-authorship network of co-authors of Mark Reid

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Reid. A scholar is included among the top collaborators of Mark Reid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Reid. Mark Reid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen: A 12-month, randomized, double-blind, placebo-controlled trial 2021 ·Travel Medicine and Infectious Disease ·(unknown), (unknown), Víctor H. González, Janet H. Ransom, Charles Scott, Geoffrey S. Dow, Mark Reid, Bryan Smith, Victor E. Zottig, Lisa Read, (unknown), Fred K. Chen	7
2	Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study 2018 ·Clinical Infectious Diseases ·James McCarthy, Bryan Smith, Mark Reid, Jonathan Berman, Louise Marquart, (unknown), Leanne West, Lisa Read, (unknown)	17
3	Tafenoquine is not neurotoxic following supertherapeutic dosing in rats 2017 ·Travel Medicine and Infectious Disease ·Geoffrey S. Dow, (unknown), Mark Reid, Bryan Smith, Stephen Toovey	5
4	Culturing the freshwater hydromedusa,Craspedacusta sowerbiiunder controlled laboratory conditions 2015 ·Invertebrate Reproduction & Development ·(unknown), Mark Reid, (unknown)	18
5	A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area 2014 ·Malaria Journal ·Geoffrey S. Dow, William F. McCarthy, Mark Reid, Bryan Smith, Douglas B. Tang, G. Dennis Shanks	30
6	Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine : randomized, double-blind, 5-year phase II study in healthy adults. 2011 ·QUT ePrints (Queensland University of Technology) ·Peter Nasveld, (unknown), (unknown), (unknown), Sutee Yoksan, John Aaskov, Karen McCarthy, Niranjan Kanesa-thasan, Claude Méric, Mark Reid	2
7	Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine 2010 ·Human Vaccines ·Peter Nasveld, Joanne Marjason, (unknown), John Aaskov, Suzanne Elliott, Karen McCarthy, Niranjan Kanesa-thasan, Emmanuel Feroldi, Mark Reid	29
8	Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine 2010 ·Human Vaccines ·Peter Nasveld, (unknown), (unknown), (unknown), Sutee Yoksan, John Aaskov, Karen McCarthy, Niranjan Kanesa-thasan, Claude Méric, Mark Reid	45
9	Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. 2010 ·PubMed ·Peter Nasveld, Joanne Marjason, (unknown), John Aaskov, Suzanne Elliott, Karen McCarthy, Niranjan Kanesa-thasan, Emmanuel Feroldi, Mark Reid	1
10	Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects 2009 ·Antimicrobial Agents and Chemotherapy ·Peter Nasveld, Michael D. Edstein, Mark Reid, Leonard A. Brennan, Ivor Harris, Scott Kitchener, Peter A. Leggat, Philip Pickford, (unknown), Colin Ohrt, William R. Prescott	88
11	Population Pharmacokinetics of Tafenoquine during Malaria Prophylaxis in Healthy Subjects 2007 ·Antimicrobial Agents and Chemotherapy ·Bruce Charles, Ann K. Miller, Peter Nasveld, Mark Reid, Ivor Harris, Michael D. Edstein	27
12	EXPERIMENTAL INFECTION OF CULEX ANNULIROSTRIS, CULEX GELIDUS, AND AEDES VIGILAX WITH A YELLOW FEVER/JAPANESE ENCEPHALITIS VIRUS VACCINE CHIMERA (CHIMERIVAX™-JE) 2006 ·American Journal of Tropical Medicine and Hygiene ·Mark Reid, (unknown), (unknown), (unknown), Kym Lowry, John Aaskov, Farshad Guirakhoo, Thomas P. Monath	22
13	Sustained transmission of dengue virus type 1 in the Pacific due to repeated introductions of different Asian strains 2004 ·Virology ·Atchareeya A-nuegoonpipat, Alain Berlioz-Arthaud, Vincent Chow, (unknown), Kym Lowry, Lê Quynh, (unknown), Alyssa T. Pyke, Mark Reid, Jean‐Marc Reynes, (unknown), Hlaing Myat Thu, Sook‐San Wong, Edward C. Holmes, John Aaskov	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact